2026-10-30

Your essential 340B briefing for hospital and clinic executives.

Recent developments surrounding the 340B program reveal ongoing tensions between drug manufacturers and healthcare providers. Missouri Attorney General Catherine Hanaway has ordered Eli Lilly to cease its demands for 340B claims data. This follows a lawsuit filed by five Massachusetts hospitals against the company for cutting off 340B discounts due to similar data refusals. The American Hospital Association has expressed support for the SUSTAIN 340B Act and called for revisions to its provisions. Concurrently, the PROTECT 340B Act has been introduced to address the exploitation of the program by pharmacy benefit managers and insurers. An HHS report has criticized the program’s expansion, suggesting a shift towards profit over patient care, further complicating the situation for covered entities reliant on 340B discounts.

EXECUTIVE SUMMARY
01
Missouri AG orders Eli Lilly to cease 340B data demands.
Missouri Attorney General Catherine Hanaway issued a cease-and-desist letter to Eli Lilly, demanding an end to its 340B claims data requirement.

02
Massachusetts hospitals sue Eli Lilly over 340B data policy.
Five Massachusetts hospitals filed a lawsuit against Eli Lilly for unlawfully cutting off 340B discounts over claims data refusal.

03
AHA backs SUSTAIN 340B Act with proposed revisions.
The AHA supports the SUSTAIN 340B Act but seeks changes to several provisions in a letter to its sponsors.

04
PROTECT 340B Act introduced to curb PBM, insurer practices.
Reps. Matsui and Mann introduced the PROTECT 340B Act to prevent PBM and insurer exploitation of the 340B program.

05
HHS report criticizes 340B program’s growth and profit focus.
An HHS report states the 340B program has expanded beyond its original intent, prioritizing hospital profit over patient care.

Source: TechTarget

06
Drugmakers seek to intervene in 340B rebate lawsuit.
Drugmakers, including AbbVie and PhRMA, filed motions to intervene in a lawsuit challenging HRSA’s 340B Rebate Model Pilot Program.

07
SUSTAIN 340B Act aims to codify program rules.
The SUSTAIN 340B Act seeks to establish clear rules for the 340B program, including contract pharmacy use and data clearinghouse.

Source: AHA

08
340B Rebate Model Pilot faces potential delay by new bill.
A new bill proposes delaying the 340B Rebate Model Pilot for two years, requiring upfront discounts instead.

EXECUTIVE SUMMARY — KEY TAKEAWAYS
Most important 340B implication. The ongoing legal and legislative battles surrounding the 340B program present a critical implication for covered entities: the potential erosion of access to discounted medications. As drug manufacturers like Eli Lilly push back against data requirements, hospitals and health systems may face increased challenges in securing the financial benefits that the 340B program was designed to provide. This could lead to higher drug costs for vulnerable populations, undermining the program’s original intent to provide patient care and access to necessary medications. The introduction of new legislation, such as the PROTECT 340B Act, aims to safeguard these discounts, but the effectiveness of such measures remains to be seen amidst growing scrutiny and criticism of the program’s structure and impact.
Emerging risks.

  • Hospitals face potential loss of 340B discounts if unable to comply with data demands.
  • Drugmakers may face increased legal challenges over 340B policies.
  • Legislative changes could alter 340B program rules, impacting hospital operations.
  • Non-compliance with new rules could result in financial penalties for PBMs and insurers.
  • Changes in reimbursement rates may affect hospital revenue streams.
Emerging opportunities.

  • Hospitals can use legislative support to strengthen 340B program participation.
  • New bills may provide clearer guidelines and protections for covered entities.
  • Potential for improved negotiation positions with drug manufacturers.
  • Opportunity to influence policy through active engagement with lawmakers.
  • Hospitals can improve compliance strategies to meet new transparency requirements.
Key actions for providers.

  • Hospitals should review and adapt to new 340B compliance requirements.
  • Engage with lawmakers to support favorable 340B legislation.
  • Monitor legal developments in 340B-related lawsuits.
  • Prepare for potential changes in reimbursement models and financial impacts.
  • Strengthen internal data management systems to meet transparency demands.
TOP STORIES
Missouri AG orders Eli Lilly to end 340B claims data requirement.
Becker’s Hospital Review · October 27, 2026
  • Missouri AG Catherine Hanaway issued a cease-and-desist letter to Eli Lilly.
  • The letter demands an end to claims data requirements for 340B discounts.
  • Failure to comply may lead to enforcement action under state law.
Massachusetts hospitals sue Eli Lilly over 340B data demands.
Becker’s Hospital Review · October 27, 2026
  • Five Massachusetts hospitals filed a lawsuit against Eli Lilly.
  • The lawsuit challenges Eli Lilly’s demand for patient claims data.
  • Hospitals allege violations of Massachusetts’ consumer protection law.
AHA backs SUSTAIN 340B Act, seeks revisions.
Becker’s Hospital Review · October 29, 2026
  • The AHA supports the SUSTAIN 340B Act.
  • The Act aims to codify rules for the 340B program.
  • AHA requested changes to several provisions in a letter to sponsors.
FEDERAL POLICY & REGULATORY DEVELOPMENTS
PROTECT 340B Act introduced to curb PBM, insurer practices.
matsui.house.gov · October 29, 2026
  • Reps. Matsui and Mann introduced the PROTECT 340B Act.
  • The Act aims to prevent PBM and insurer exploitation of the 340B program.
  • It includes provisions for a third-party clearinghouse and civil penalties.
HHS report criticizes 340B program’s growth and profit focus.
TechTarget · October 12, 2026
  • HHS report states 340B program prioritizes hospital profit over patient care.
  • The report cites growth in program participation and costs.
  • Hospitals oppose rebate models, citing cash-flow and administrative burdens.
340B PROGRAM DEVELOPMENTS
340B Rebate Model Pilot faces potential delay by new bill.
Becker’s Hospital Review · October 13, 2026
  • New bill proposes delaying the 340B Rebate Model Pilot for two years.
  • The delay would require upfront discounts instead of rebates.
  • The bill aims to give Congress time for broader 340B reform.
LITIGATION & ENFORCEMENT WATCH
Court Matter Date
D. Mass. Massachusetts hospitals v. Eli Lilly, claims data dispute. [source] October 27, 2026
D. Me. American Hospital Association v. Kennedy, drugmakers seek intervention. [source] October 16, 2026
MANUFACTURER WATCH
Manufacturer Action Date
Eli Lilly Sued by Massachusetts hospitals for 340B data demands. [source] October 27, 2026
WHAT TO WATCH NEXT
  • HRSA’s 340B Rebate Model Pilot Program to begin January 2027. [source]
  • Potential legislative action on the PROTECT 340B Act. [source]
  • Missouri AG’s deadline for Eli Lilly to end 340B data policy by November 26. [source]
  • Congressional review of the SUSTAIN 340B Act provisions. [source]
End of briefing.

This briefing is provided for informational purposes only and does not constitute legal, regulatory, financial, or compliance advice. Automated summarization may contain errors or omissions, and source materials may change after publication. Recipients should independently verify all information against the cited primary sources before relying on it.

© 2026 MedMatrix Rx. All rights reserved.

Post information

Schedule Your 340B Assessment

Connecting healthcare organizations to their full potential through compliant 340B optimization.